• Title/Summary/Keyword: intravenous toxicity

Search Result 147, Processing Time 0.025 seconds

Acute and Subacute Toxicity Studies of Water Soluble Dimethyl Dimethoxy Biphenylate Derivative in Rats (수용성 DDB유도체의 주사제 개발을 위한 급성독성 및 아급성독성시험연구)

  • 김준규;박창원;이윤숙;김정구;이치호;조대현
    • Toxicological Research
    • /
    • v.13 no.4
    • /
    • pp.423-433
    • /
    • 1997
  • The acute and subacute toxicity of water soluble dimethyl dimethoxy biphenylate derivative (new DDB), hepatitis therapeutics, were investigated in SD rats. In the acute toxicity study, body weights and clinical signs were observed for 7 days after the intravenous injection of new DDB at doses of 140, 182, 236, 307 and 400 mg/kg(r=1.3). Death. Severe convulsion, tremor and decrease motor activity were observed in almost treated groups (except the 140 mg/kg treated group). Changes of body weight in treated groups were not significantly different from control group. Autopsy of survived animals revealed no abnormal gross findings related to new DDB. As a results, the $LD_{50}$ values of new DDB were 244.1 mg/kg for male and 232.5 mg/kg for female. In subacute toxicity study, body weights and clinical signs were observed after intravenous injection of new DDB at doses of 57, 75 and 100 mg/kg/day for 28 days. Death, decrease motor activity and tremor were observed above 75 mg/kg treated groups. Statistically significant changes were observed in hematological and biochemical parameters of new DDB-treated groups; however, these changes were within normal range and had no relationship with dosage. Several abnormal findings were observed in microscopic examination of tissue; however, these findings were not caused by new DDB but environmental factor. The no toxic dose level of new DDB were estimated to be 57 mg/kg/day in this study.

  • PDF

Acute Toxicity of Enrofloxacin-Colistin Combinations after a Single Oral and Intravenous Administration in ICR Mice (ICR계 마우스에서 Enrofloxacin과 Colistin 복합체의 단회 경구 및 정맥투여시 급성독성)

  • Kim, Min-Kyu;Park, Seung-Chun;Yun, Hyo-In;Oh, Tae-Kwang;Choi, Yang-Woong
    • Toxicological Research
    • /
    • v.14 no.3
    • /
    • pp.385-391
    • /
    • 1998
  • The study was carried out to evaluate the acute toxicity of enrofloxacin-colistin combination via a single oral(p.o.)and intravenous(i.v.) administration in ICR mice. All procedures of the test were performed by the established regulation of Korean National Institute of Safety Research (1994. 4.14). The maximal dose of oral and intravenous routes was 5,000mg/kg and 90mg/kg, consisting with each 6 groups including control of male and female, respectively. As the results, $LD_{50}$m}'s of the combinations showed 3,075mg/kg (f)and 2,564mg/kg(m) after oral administrations, together with 48mg/kg(f) and 40mg/kg(m) after intravenous administration. These facts indicated that acute toxicitiy of enrofloxacin-colistin combination were different depending on the administration routes and sexes in ICR mice. In conclusion, the route of enrofloxacin-colistin combination must not choose as i.v. route administration in terms of acute toxicity based on $LD_{50}$.

  • PDF

Study for Three-months Subacute Toxicity of Water-soluble DDB Derivative in Beagle Dogs (비글개에서 수용성 DDB 유도체의 3개월 반복투여독성에 관한 연구)

  • 김민영;손장원;신민기;배미옥;김정현;방명주;최진혁;김준성;문전옥
    • Toxicological Research
    • /
    • v.16 no.3
    • /
    • pp.239-253
    • /
    • 2000
  • This study was carried out to evaluate the three months subacute intravenous toxicity of water soluble dimethyl dimethoxy biphenylate derivative (DDB-S), a newly formulated therapeutic agent for hepatitis, in Beagle dogs. Groups of 12 male and 12 female dogs were given different dosage of DDB-S, 10 mg/kg/day (high dose group), 5 mg/kg/day (middle dose group), 2.5 mg/kg/day (low dose group) and 0 mg/kg/day (control group) for three months by intravenous route. 1n the three months intravenous toxicity study, there were neither dead animals nor significant changes of body weights during the experimental period. 1n addition to, no significant DDB-S related changes were found in clinical signs, urinalysis and other findings. Statistical changes were observed in hematological. biochemical, partial thromboplastin time (PIT) and organ weight parameters of treated groups. However, these alteration had no relationship with dosage. No histopathological lesions were observed in both control and treated animals. Above data suggest that no observed adverse effect level of test materials in Beagle dogs might be over 10 mg/kg/day in this study.

  • PDF

Acute Toxicity and Four-week Intravenous Toxicity Studies of Intralipidos (Intralipidos에 대한 급성독성 및 4주간 정맥 내 반복투여 독성시험)

  • Li, Guang-Xun;Che, Jeong-Hwan;Kang, Byeong-Cheol;Lee, Won-Woo;Ihm, Jong-Hee;Jung, Ji-Yun;Yi, Beoung-Hi;Nam, Jeong-Seok;Park, Jae-Hak;Lee, Yong-Soon
    • Toxicological Research
    • /
    • v.14 no.3
    • /
    • pp.443-452
    • /
    • 1998
  • This sutdy was carried out to investigate the acute toxicity and foru-week intravenous toxicity of the intralipidos in rats and rabbits. The acute toxicity study of Intralipidos was performed in Spragur-Dawley (SD) rats. Intralipidos was administered by intravenous to maximum dose 200 ml/kg. $LD_{50}$ of intralipidos was found 139.5ml/kg and 153.8ml/kg in male female SD rats. Four-week toxicity of intralipidos using New Zealand White Rabbit and SD rats. The Rabbit and Rats were administered by intravenous seven days per week for 28 days, with dosage of 15, 6, 2 ml/kg/day and 20, 6, 2ml/kg/day, respectively. Animals treated with intralipidos did not cause any death and show any clinical signs. They did not show any significant changes of body weight, feed uptake and water consumption. They were not significantly different from the control group in urinalysis, ocular examination hematological, serum biochemical value and histopathological examination. Therefore, Intralipidos was not indicated to have any toxic effect in the Rabbits and Rats, when it was administrated by intravenous below the dosage 15ml/kg/day and 20 ml/kg/day for four weeks.

  • PDF

Intravenous Single-dose Toxicity of Mountain Ginseng Pharmacopuncture in Sprague-Dawley Rats

  • Lee, Kwangho;Sun, Seungho;Yu, Junsang;Lim, Chungsan;Kwon, Kirok
    • Journal of Pharmacopuncture
    • /
    • v.17 no.3
    • /
    • pp.50-56
    • /
    • 2014
  • Objectives: Mountain ginseng pharmacopuncture (MGP) is an extract distilled from either mountain cultivated ginseng or mountain wild ginseng. This is the first intravenous injection of pharmacopuncture in Korea. The word intravenous does not discriminate between arteries, veins, and capillaries in Oriental Medicine, but only the vein is used for MGP. The aim of this study is to evaluate the intravenous injection toxicity of MGP through a single-dose test in Sprague-Dawley (SD) rats. Methods: Male and female 6-week-old SD rats were injected intravenously with MGP (high dosage of 20 mL/kg or low dosage of 10 mL/kg). Normal saline was injected into the rats in the control group by using the same method. After the rats has treated, we conducted clinical observations, body-weight measurements and histological observations. Results: In this study, no mortalities were observed in any of the experimental groups. Also, no significant changes by the intravenous injection of MGP were observed in the body weights, or the histological observations in any of the experimental groups compared to the control group. The lethal dose for intravenous injection of MGP was found to be over 20 mL/kg in SD rats. Conclusion: Considering that the dosage of MGP generally used each time in clinical practice is about 0.3 mL/kg, we concluded with confidence that MGP is safe pharmacopuncture.

Acute Toxicity and Antigenicity of Guamerin (Guamerin의 단회투여독성 및 항원성 평가)

  • 조명행;김민영;손장원;배미옥;김정현;신민기;방명주;김경연;최승진
    • Toxicological Research
    • /
    • v.16 no.1
    • /
    • pp.83-87
    • /
    • 2000
  • This study was carriet out to evaluate the acute intravenous toxicity and antigenicity of Guamerin, newly developed by Mogam Biotechnology Research Institute (MBRI). In acute intravenous toxicity test, ICR mice were administered intravenously with single dose of 1,000mg/kg, and body weights and clinical signs were observed for 14 days. No dead animal, clinical signs, body weight change and abnormal autopsy findings were found in control and Gumerin treated group. Therefore, the 50% lethoal dose (LD50) of Guamerin for ICR mice was more than 1,000mg/kg on intravenous route for male and female. And the antigenic potential of Guamerin was examined by active systemic anaphylaxis(ASA) and passive cutaneous anaphylaxis(PCA) tests. In the ASA test, low and high doses (10 and 100ug/animal, respectiwely) of Guamerin were administed subcutaneously to guinea pigs for 9 times 3 weeks. All experimental groups showed negative responses whereas the positive control group given ovalbumin plus Freunds complete adjuvant (FCA) showed severe anaphylactic responses. PCA test using rats with mice anti-serum against Guamerin, low and high doses(10 and 100 ug/animal, respectively) of Guamerin were administered to mice for 9 times in 3 weeks. The anti-serum against Guamerin was administed intradermally at the back of rats, however, any positive responses were not detected in the experimental groups. These results strongly indicate that Guamerin does not induce IgE production and is not a PCA reaction inducer under these experimental conditions.

  • PDF

Intravenous Single Dose Toxicity of Sweet Bee Venom in Sprague-Dawley Rats

  • Lee, Kwang-Ho;Yu, JunSang;Sun, Seungho;Kwon, KiRok
    • Journal of Pharmacopuncture
    • /
    • v.18 no.3
    • /
    • pp.49-56
    • /
    • 2015
  • Objectives: Anaphylactic shock can be fatal to people who become hypersensitive when bee venom pharmacopuncture (BVP) is used. Thus, sweet bee venom (SBV) was developed to reduce these allergic responses. SBV is almost pure melittin, and SBV has been reported to have fewer allergic responses than BVP. BVP has been administered only into acupoints or intramuscularly, but we thought that intravenous injection might be possible if SBV were shown to be a safe medium. The aim of this study is to evaluate the intravenous injection toxicity of SBV through a single-dose test in Sprague-Dawley (SD) rats. Methods: Male and female 6-week-old SD rats were injected intravenously with SBV (high dosage: 1.0 mL/animal; medium dosage: 0.5 mL/animal; low dosage: 0.1 mL/animal). Normal saline was injected into the control group in a similar method. We conducted clinical observations, body weight measurements, and hematology, biochemistry, and histological observations. Results: No death was observed in any of the experimental groups. Hyperemia was observed in the high and the medium dosage groups on the injection day, but from next day, no general symptoms were observed in any of the experimental groups. No significant changes due to intravenous SBV injection were observed in the weights, in the hematology, biochemistry, and histological observations, and in the local tolerance tests. Conclusion: The results of this study confirm that the lethal dose of SBV is over 1.0 mL/animal in SD rats and that the intravenous injection of SBV is safe in SD rats.

Acute Toxicity Study of Recombinant Granulocyte-Macrophage Colony Stimulating Factor (LBD-005) in ICR mice

  • Kim, Hyoung-Chin;Song, Si-Whan;Cha, Shin-Woo;Shin, Chun-Chul;Ha, Chang-Su;Han, Sang-Seop
    • Biomolecules & Therapeutics
    • /
    • v.1 no.2
    • /
    • pp.270-274
    • /
    • 1993
  • The acute toxicity of a recombinant granulocyte-macrophage colony stimulating factor (code name: LBD-005) was evaluated in both sexes of ICR mice, 5~6 weeks old, by the oral, subcutaneous and intravenous routes of administration. Based on the results of the acute toxicity study, LBD-005 was not considered to induce any toxic effect on the mice in mortalities, clinical findings, body weights and gross findings. It is suggested that $LD_50$ values in mice would be >48 mg/kg in the oral route and >24 mg/kg in the subcutaneous or intravenous route.

  • PDF

ACUTE TOXICITY STUDY OF RECOMBINANT GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR (LBD-005) IN RATS

  • Kim, Hyoung-Chin;Boohyon Kang;Ha, Chang-Soo;Han, Sang-Seop
    • Toxicological Research
    • /
    • v.8 no.1
    • /
    • pp.41-48
    • /
    • 1992
  • The actue toxicity of a recombinant granulocyte macrophage colony-stimulating factor (code name: LBD-005) was evaluated in both sexes of Sprague-Dawley rats, 4 weeks old, by the oral, subcutaneous and intravenous routes of administration. LBD-005 in the acute toxicity study in the rats was not considerde to induce any toxicological effect on the rats in mortalities, clinical findings, body weights and gross findings. It is suggested that $LD_{50}$ values in rats would be >48 mg/kg in the oral route and >12 mg/kg in the subcutaneous or intravenous route.

  • PDF

Acute toxicity of DA-3030(G-CSF) in rats and mice (랫드와 마우스에서 DA-3030(G-CSF)의 급성독성에 관한 연구)

  • 이영순;조재진;김영석;남정석;박재학;이순복
    • Biomolecules & Therapeutics
    • /
    • v.2 no.3
    • /
    • pp.256-259
    • /
    • 1994
  • This study was performed to evaluate the acute toxicity of DA-3030(granulocyte-colony stimulating factor, G-CSF) in mice and rats via intragastrical and intravenous routes. DA-3030(G-CSF) in the acute toxicity study did not induce any toxic signs in the mice and rats in mortalities, clinical findings, body weights and gross findings. It is suggested that LD$_{50}$ values in mice and rats would be >13, 800 $\mu\textrm{g}$/kg in the oral route and >6, 900 $\mu\textrm{g}$/kg in the intravenous route.e.

  • PDF